Coronary heart disease remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%. In practical terms, that means that many who “look healthy” go on to have CHD and preventable cardiac events such as a heart attack.
For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops. Healthcare providers ask about cholesterol levels, blood pressure, smoking history, diabetes status, family history and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling is that so much of this is preventable.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level. By looking beyond traditional risk factors, these tests aim to identify individuals who are at elevated risk despite appearing healthy based on standard assessments. The company’s approach could help close a critical blind spot in current cardiovascular screening protocols.
The implications for patients and the healthcare system are significant. If widely adopted, molecular precision testing could reduce the number of unexpected heart attacks and improve outcomes for the millions of Americans who are unknowingly at risk. For Cardio Diagnostics, this represents a potential growth opportunity as the company seeks to establish its tests as a complement—or alternative—to conventional risk calculators.
Investors should note that forward-looking statements in this article involve risks and uncertainties. Details are available in the company’s filings with the SEC. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
